Primary Hyperoxaluria: Pathophysiology, Diagnosis, and New RNAi Treatment Approaches

Primary Hyperoxaluria: Pathophysiology, Diagnosis, and New RNAi Treatment Approaches Posted By:
...

PH Pathophysiology
Primary hyperoxalurias (PHs) are rare and caused by a genetic defect of glycolate metabolism in which the body produces too much oxalate, which is deposited in various organs as calcium oxalate. Oxalate is excreted in the urine, and overproduction of oxalate can lead to kidney stones, nephrocalcinosis, and kidney failure if left untreated. 

Three distinct forms of PH have been identified: type 1 (PH1), type 2 (PH2), and type 3 (PH3), which are caused by autosomal recessive mutations in the AGXT, GRHPR, and HOGA1 genes, respectively. PH1 is the most common and most severe of the 3 types, with more rapid decline in kidney function and the development of end-stage kidney disease in one half of patients by the time they reach 20 years of age. PH1 can be diagnosed at any age, but patients typically present with symptoms during childhood. Patients with PH1 may have various genetic mutations in AGXT that result in deficiency in alanine‒glyoxylate aminotransferase (AGT). AGT deficiency results in insufficient transamination of glyoxylate to glycine, and as a result, glyoxylate is converted to oxalate by lactate dehydrogenase.

PH Symptoms
Many patients present with kidney stones and other nonspecific symptoms, often in childhood, which leads to referral to urology. Calcium oxalate crystals can be found in the urine, and symptoms can mimic kidney infections. Because PH is rare, pediatricians and urologists may lack clinical suspicion, which can lead the patient to nephrology for evaluation. To optimize patient outcomes, early recognition and multidisciplinary awareness are key. Urine and blood tests, along with kidney imaging and genetic testing, can help healthcare professionals determine the diagnosis of PH.

Emerging Therapy
The goal of PH treatment has been lowering the oxalate level by potassium citrate and vitamin B6. RNA interference (RNAi) therapy has introduced a recent advancement in the management of PH1. Both lumasiran and nedosiran are approved by the FDA for the treatment of PH1 in adults and children. RNAi therapy works as a targeted approach by silencing specific genes, such as the genes responsible for oxalate production. RNAi therapy introduces small RNA molecules that are designed to match the messenger RNA (mRNA) of a specific gene. When they pair up, the destruction of the mRNA is prompted to prevent the production of the enzyme that was leading to excess oxalate.

Lumasiran is administered by SC injections with 3 starting doses administered monthly, followed by an ongoing dose 1 month after the last starting dose. It is indicated in infants through adulthood. Lumasiran is meant to be given by a healthcare professional from a single-dose vial. Nedosiran is approved for patients 9 years of age and older with a preserved kidney function. It is available in 2 strengths—128 mg or 160 mg—to be given subcutaneously once monthly at home in a prefilled syringe. Nedosiran will be available for prescribing in early 2024.

Practice Recommendations
An expert consensus statement on the diagnosis and management of PH in adults and children from the European Rare Kidney Disease Reference Network and OxalEurope was published in January 2023 (PMID: 36604599). Healthcare professionals can find a stepwise approach for the diagnosis and management of patients with PH, including the use of targeted RNAi therapies in PH1. The algorithm indicates starting patients with vitamin B6, citrate, and hyperhydration, followed by RNAi therapy for those unresponsive or with a vitamin B6 mutation.

Patients with PH1 need to stay vigilant with a low-oxalate diet to reduce the burden on the kidneys and have regular follow-up appointments. Education on disease awareness, diagnosis, and new and emerging treatment strategies for patients with rare diseases such as PH1 is imperative. RNAi therapy offers an exciting treatment option for patients with PH to improve life expectancy and quality of life. This innovative therapy can make PH more manageable with remarkable improvements. Accessibility of RNAi therapy is a concern for patients and healthcare professionals, but patient support programs are available.


Share

Filed under: Miscellaneous

Sign up to receive posts from The Exchange

Related
Sexual Health in Patients With Rheumatic Disease: How to Ask Sensitive Questions in a Clinical Setting

Sexual Health in Patients With Rheumatic Disease: ...

It is not easy to ask our patients about sexual health and functioning. The European Alliance of Ass ...

Filed under: Miscellaneous, Rheumatology


Continue Reading
Hope Tempered With Reality

Hope Tempered With Reality

"We don't want to lose hope or let Mom think we don't believe she'll get better." For palliative car ...

Filed under: Miscellaneous, Practice Management/Career


Continue Reading
How Much News Is Too Much News?

How Much News Is Too Much News?

With the COVID-19 pandemic and influx of global interest in current events, many people started cons ...

Filed under: Health Policy and Trends, Miscellaneous


Continue Reading
Is Gardening Good for Your Health?

Is Gardening Good for Your Health?

As a result of the COVID-19 pandemic, many people spend much more time at home. One of the at-home a ...

Filed under: Miscellaneous


Continue Reading
Toxic Culture and Driving Meaningful Change

Toxic Culture and Driving Meaningful Change

I have recently taken an increased interest in podcasts. One of my favorites is Brené Brown's Dar ...

Filed under: Miscellaneous, Practice Management/Career


Continue Reading
May Is Older Americans Month

May Is Older Americans Month

In the month of May, we celebrate Older Americans Month, led by the Administration for Community Liv ...

Filed under: Miscellaneous


Continue Reading